Purple Biotech Ltd. SEC filings document foreign private issuer current reports for a clinical-stage oncology biotechnology company and its PPBT American depositary shares. Recent Form 6-K filings attach press releases and corporate presentations covering CAPTN-3, IM1240 and IM1305, preclinical and toxicology data, oncology development plans, collaboration announcements, scientific advisory activity, operating results, and risk-related forward-looking disclosures.
The filing record also reflects capital-structure and market-status matters, including ADS ratio disclosures and Nasdaq minimum bid price compliance. The company’s 6-K reports are incorporated by reference into registration statements on Form F-3 and Form S-8, linking current reports to shelf registration and equity-plan disclosure frameworks.
Purple Biotech Ltd. (PPBT) filed a Form 6-K on 23 June 2025. The sole purpose of the submission is to furnish a press release titled “Purple Biotech Announces Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress.” The press release is included as Exhibit 99.1.
The filing contains no financial statements, earnings figures, or transactional details. It merely places the press release—and all statements therein—into the U.S. public record and incorporates the document by reference into numerous outstanding registration statements (Forms S-8, F-1 and F-3) dating from 2016 through 2024. The Company also confirms that Chief Executive Officer Gil Efron signed the submission on behalf of the registrant.
Because the actual press release text is not included, investors only learn that Purple Biotech believes its CAPTN-3 tri-specific antibody platform demonstrates “significant advantages” and that these data were highlighted at the European Association for Cancer Research (EACR) 2025 Annual Congress. No quantitative efficacy results, clinical-stage milestones, or development timelines are provided in this 6-K.